New Study Reports Two Thirds Of Renal Recipients Switched To myfortic(R) Experience An Improvement In Gastrointestinal Symptom Burden

A large-scale open label non-comparative study published this week in Transplantation demonstrates that, following conversion from mycophenolate mofetil therapy (MMF) to myfortic(R) (mycophenolic acid) delayed-release tablets, gastrointestinal (GI) complaints in kidney recipients are improved and sustained over the three month trial1. Up to 45 percent of recipients experience GI side effects with MMF2. [click link for full article]

More: continued here

Comments are closed.



Get Rx Pharmacy - : Get Rx Pharmacy
Reliable Prescriptions Online - : Reliable Prescriptions Online
Rx Free - : Rx Free
RX Pills Pharmacy - Buy Drugs: RX pills pharmacy
RX Pill Vault - Buy Drugs: Interested in buying Rx pills? Here is the link for you.
My super dtrug store - : My super dtrug store
Prescript Medicine - : Prescript Medicine
Latest News...